Dr. Reddy's, Glaxo Settle Imitrex Patent Dispute

Law360, New York (October 10, 2006, 12:00 AM EDT) -- Dr. Reddy’s Laboratories has reached a patent litigation settlement with GlaxoSmithKline PLC and gained permission to sell a generic version of popular anti-headache drug Imitrex in the United States.

India-based drug company Dr. Reddy’s said on Tuesday that it plans to distribute an authorized generic version of sumatriptan succinate in 25mg, 50mg and 100mg tablets.

The expected launch date in late 2008 precedes the expiration of the Imitrex patents on Feb. 6, 2009.

Other terms of the settlement agreement were not disclosed, and the agreement is...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.